Immunotherapy with plasmid DNA encoding mycobacterial hsp65 in association with chemotherapy is a more rapid and efficient form of treatment for tuberculosis in mice.
about
Intranasal vaccination with messenger RNA as a new approach in gene therapy: use against tuberculosisHeat shock proteins: stimulators of innate and acquired immunityImmunogenicity without Efficacy of an Adenoviral Tuberculosis Vaccine in a Stringent Mouse Model for Immunotherapy during TreatmentEfficacy of Mycobacterium indicus pranii immunotherapy as an adjunct to chemotherapy for tuberculosis and underlying immune responses in the lungCombined immunization using DNA-Sm14 and DNA-Hsp65 increases CD8+ memory T cells, reduces chronic pathology and decreases egg viability during Schistosoma mansoni infectionProtection against tuberculosis by a single intranasal administration of DNA-hsp65 vaccine complexed with cationic liposomes.Efficacy and Safety of Mycobacterium indicus pranii as an adjunct therapy in Category II pulmonary tuberculosis in a randomized trialHelminth coinfection does not affect therapeutic effect of a DNA vaccine in mice harboring tuberculosis.Molecular characterization of the Corynebacterium pseudotuberculosis hsp60-hsp10 operon, and evaluation of the immune response and protective efficacy induced by hsp60 DNA vaccination in mice.Protective and therapeutic efficacy of Mycobacterium smegmatis expressing HBHA-hIL12 fusion protein against Mycobacterium tuberculosis in miceImmunotherapeutic efficacy of recombinant Mycobacterium smegmatis expressing Ag85B-ESAT6 fusion protein against persistent tuberculosis infection in miceTherapeutic DNA vaccine reduces schistosoma mansoni-induced tissue damage through cytokine balance and decreased migration of myofibroblasts.Immunotherapeutic role of Ag85B as an adjunct to antituberculous chemotherapyRifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model.Immune responses to tuberculosis in developing countries: implications for new vaccines.Update in tuberculosis 2005.Ag85A/ESAT-6 chimeric DNA vaccine induces an adverse response in tuberculosis-infected mice.Stringent Response Factors PPX1 and PPK2 Play an Important Role in Mycobacterium tuberculosis Metabolism, Biofilm Formation, and Sensitivity to Isoniazid In Vivo.The impact of transcriptomics on the fight against tuberculosis: focus on biomarkers, BCG vaccination, and immunotherapy.Immunotherapy for TB.Adjunct immunotherapy with Ag85 complex proteins based subunit vaccine in a murine model of Mycobacterium tuberculosis infection.Adjunctive immunotherapy with α-crystallin based DNA vaccination reduces Tuberculosis chemotherapy period in chronically infected mice.Synergy of chemotherapy and immunotherapy revealed by a genome-scale analysis of murine tuberculosis.DNA-hsp65 vaccine as therapeutic strategy to treat experimental chromoblastomycosis caused by Fonsecaea pedrosoi.Efficient tuberculosis treatment in mice using chemotherapy and immunotherapy with the combined DNA vaccine encoding Ag85B, MPT-64 and MPT-83.Influence of a DNA-hsp65 vaccine on bleomycin-induced lung injury.Mycobacterium tuberculosis GroEL2 modulates dendritic cell responses.Novel nanoparticle delivery systems for rifampicin: an effective strategy against tuberculosis?Treatment of multi-drug-resistant tuberculosis in mice with DNA vaccines alone or in combination with chemotherapeutic drugs.Phase I trial of DNA-hsp65 immunotherapy for advanced squamous cell carcinoma of the head and neckNanoparticle Vaccines Against Infectious DiseasesProtective efficacy of different strategies employingMycobacterium lepraeheat-shock protein 65 against tuberculosis
P2860
Q21256673-12D6C153-D695-4CC4-8815-5BF15460D346Q26829100-D1B46A43-6886-4F38-9CC4-2C515137FEE0Q27306144-C413ADDA-20FA-44F8-BA44-F0E4FDFA5B52Q28481571-9B9B64EE-248C-4C65-BCF7-D2F3E85D849AQ30578697-DDAA5277-A8CC-4B61-B550-B4232C8B385EQ33353872-9501F500-50A8-4922-AEE1-3F798E0AF536Q33793948-51054CA4-9369-47BC-867F-5EB6C97ED270Q33900309-E70CDB76-58CE-4C37-8626-E10E9AF0F239Q33966543-20C5C1AD-CCFF-430D-95FF-22BC31F89E61Q34171520-7965E871-7322-46BB-AEA6-02B0B89B05BBQ34271591-D920BA3E-77D2-4F4A-863D-B9C03E7C824DQ35070198-1115C9B0-7DBA-4E05-B449-72E2EAB65591Q35124651-4FF1327A-E084-45A4-8210-657FE7ECA0AFQ35754209-348BFCEF-9684-41AC-87F1-92156E5A6A23Q36213975-5CAED658-2549-43DB-B2E3-47107DE46477Q36403165-4B46D84E-AFC9-4F85-8CA3-0D4132F928D8Q37082912-38BE1540-3351-4225-BF9A-5C7456BBCFCBQ37358614-0CC3EA17-451A-468C-A3C0-B39EDAA53843Q37825430-597B671C-3800-4D32-AEA4-F24A4C455BBAQ38025666-B211AEB2-4690-4558-9BE7-C2492A9CB5CEQ40014676-EC2B560C-B15F-4967-AAF3-E4448A7FA5DDQ40608583-E7D0A30D-C504-49EE-BEA1-84A0D52EB1D0Q41480039-E5C1CD32-A167-42A9-ACBE-311BA6ABFEA2Q44651481-B427A344-A235-49F0-B29F-28AA6BC1DFAFQ45875337-A1432ACE-B6D8-4C88-A0CB-F2824D400603Q46188918-6A582413-F6A2-46CE-A5FD-B91A4C31CA9FQ47407316-C237309B-70E9-4459-AEAF-71D5DB0520D0Q48801804-EA0D29B1-BF26-46F4-90A0-D1EE8294ED50Q51499941-068E5CF9-953D-43F0-A29B-F3B6164B3329Q56786021-A48C8D58-BC07-4F3E-95B1-C5DBB563B5C3Q58583890-530EF103-0860-4966-98DD-8DE1F315301AQ58863716-6950D3F5-7E18-4CED-8E75-475CAA90C353
P2860
Immunotherapy with plasmid DNA encoding mycobacterial hsp65 in association with chemotherapy is a more rapid and efficient form of treatment for tuberculosis in mice.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Immunotherapy with plasmid DNA ...... ment for tuberculosis in mice.
@en
Immunotherapy with plasmid DNA ...... ment for tuberculosis in mice.
@nl
type
label
Immunotherapy with plasmid DNA ...... ment for tuberculosis in mice.
@en
Immunotherapy with plasmid DNA ...... ment for tuberculosis in mice.
@nl
prefLabel
Immunotherapy with plasmid DNA ...... ment for tuberculosis in mice.
@en
Immunotherapy with plasmid DNA ...... ment for tuberculosis in mice.
@nl
P2093
P50
P921
P356
P1433
P1476
Immunotherapy with plasmid DNA ...... tment for tuberculosis in mice
@en
P2093
Coelho-Castelo AA
De Souza AO
Rodrigues JM
P2888
P304
P356
10.1038/SJ.GT.3302418
P577
2005-02-01T00:00:00Z